Combined Antihypertensive Therapy and Sexual Dysfunction

• Status: Unknown status
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomized,active controlled study aimed to compare the effects on sexual function of treatment with combined antihypertensive drugs.

The researchers hypothesize that:

1. Both felodipine-irbesartan combination and felodipine-metoprolol combination are effective in lowing blood pressure in patients with essential hypertension.

2. Felodipine-metoprolol combination induces a worse sexual function and a reduction of sex hormone,whereas felodipine-irbesartan combination does not impair sexual function and does not change hormone levels.

3. Oxidative stress decline after both combination regimens. Felodipine-irbesartan combination has a greater impact on oxidative stress indicators than felodipine-metoprolol combination.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LanZhou University
• Treatments: Antihypertensive Agents; Felodipine; Irbesartan; Metoprolol

Criteria

Inclusion Criteria:

• Patients with essential hypertension.

• Initial hypertension, or without taking any antihypertensive for at least one month.

• Sexual active.

Exclusion Criteria:

• Patients with secondary hypertension.

• Patients with malignant hypertension, coronary heart disease, diabetes, a history of syncope, bradycardia (heart rate <45 beats / min), atrioventricular block(Ⅱ or Ⅲ degree), sick sinus syndrome, congestive heart failure, a history of cerebral vascular accidents, serious hepatic and kidney dysfunction, a history of serious mental illness, pregnant, taking oral exogenous estrogens (including contraceptives), hysterectomy, breastfeeding, a history of alcohol or drug abuse, having serious conflict with sexual partner, severity sexual dysfunction.

• Patients refuse to answer questions, refuse to fill in the questionaires,or do not willing to take blood examination.